Pay in 4 interest-free payments of $6.52 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
In return, Zealand Pharma will pay Roche $350 million for the fixed-dose combination product involving petrelintide and Roches lead incretin asset CT-388
Biosensors for inflammation as a strategy to engineer regulatory T cells for cell therapy
After treatment with GLP-1, the number of apoptotic cells drastically reduced in the human isolated islets
Precision : Enables titration beyond currently approved pen doses
US$ 20.72
US$ 27.18
US$ 23.32
US$ 20.46
US$ 29.01
US$ 23.88
US$ 21.47
